Michalis Mastri
Overview
Explore the profile of Michalis Mastri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
506
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Mussell A, Shen H, Chen Y, Mastri M, Eng K, Bshara W, et al.
Cancers (Basel)
. 2020 Oct;
12(11).
PMID: 33114077
The Hippo signaling pathway is an evolutionarily conserved pathway that was initially discovered in and was later found to have mammalian orthologues. The key effector proteins in this pathway, YAP/TAZ,...
12.
Vaghi C, Rodallec A, Fanciullino R, Ciccolini J, Mochel J, Mastri M, et al.
PLoS Comput Biol
. 2020 Feb;
16(2):e1007178.
PMID: 32097421
Tumor growth curves are classically modeled by means of ordinary differential equations. In analyzing the Gompertz model several studies have reported a striking correlation between the two parameters of the...
13.
Dolan M, Mastri M, Tracz A, Christensen J, Chatta G, Ebos J
PLoS One
. 2019 Aug;
14(8):e0220101.
PMID: 31369645
Tyrosine kinase inhibitors (TKIs) that primarily target angiogenesis are approved to treat several cancers in the metastatic setting; however, resistance is common. Sequential treatment or 'switching' from one TKI to...
14.
Mastri M, Ebos J
Mol Cell Oncol
. 2019 May;
6(2):1575707.
PMID: 31131302
Cancer treatments can induce a form of senescence that halts cellular division while allowing continued secretion of tumor-promoting proteins. We recently found that antiangiogenic treatment resistance can lead to a...
15.
Mastri M, Tracz A, Lee C, Dolan M, Attwood K, Christensen J, et al.
Cell Rep
. 2018 Dec;
25(13):3706-3720.e8.
PMID: 30590043
VEGF receptor tyrosine kinase inhibitors (VEGFR TKIs) approved to treat multiple cancer types can promote metastatic disease in certain limited preclinical settings. Here, we show that stopping VEGFR TKI treatment...
16.
Mastri M, Lee C, Tracz A, Kerbel R, Dolan M, Shi Y, et al.
Mol Cancer Ther
. 2018 Apr;
17(7):1602-1612.
PMID: 29695634
The levels of various circulating blood proteins can change in response to cancer therapy. Monitoring therapy-induced secretomes (TIS) may have use as biomarkers for establishing optimal biological effect (such as...
17.
Dufies M, Giuliano S, Ambrosetti D, Claren A, Ndiaye P, Mastri M, et al.
Cancer Res
. 2017 Jan;
77(5):1212-1226.
PMID: 28087600
Sunitinib is an antiangiogenic therapy given as a first-line treatment for renal cell carcinoma (RCC). While treatment improves progression-free survival, most patients relapse. We hypothesized that patient relapse can stem...
18.
Mastri M, Rosario S, Tracz A, Frink R, Brekken R, Ebos J
Curr Drug Targets
. 2015 Dec;
17(15):1747-1754.
PMID: 26648063
Drug resistance remains an ongoing challenge for the majority of patients treated with inhibitors of the vascular endothelial growth factor (VEGF) pathway, a key regulator of tumor angiogenesis. Preclinical models...
19.
Karacosta L, Kuroski L, Hofmann W, Azabdaftari G, Mastri M, Gocher A, et al.
Prostate
. 2015 Nov;
76(3):294-306.
PMID: 26552607
Background: Re-activation of the transcriptional activity of the androgen receptor (AR) is an important factor mediating progression from androgen-responsive to castrate-resistant prostate cancer (CRPC). However, the mechanisms regulating AR activity...
20.
Benzekry S, Tracz A, Mastri M, Corbelli R, Barbolosi D, Ebos J
Cancer Res
. 2015 Oct;
76(3):535-47.
PMID: 26511632
Rapid improvements in the detection and tracking of early-stage tumor progression aim to guide decisions regarding cancer treatments as well as predict metastatic recurrence in patients following surgery. Mathematical models...